Abstract
Abstract Introduction: Circulating Tumor Cells (CTCs) levels are dynamic indicators of prognosis and response to therapy in metastatic breast cancer (MBC) patients (pts). CTCs levels have been reported to be higher in pts with bone than visceral metastases, respectively. However, little is known about CTCs levels in pts with BM involvement. We analysed CTC patterns in patients with either visceral, bone or BM to test the hypothesis that BM involvement would facilitate tumor cells to enter the systemic circulation as CTCs. Patients and methods: Sites and extension of metastatic disease were identified with conventional imaging. Bone metastases were diagnosed with either bone scintigraphy or CT-PET and the BM involvement was documented histologically by BM biopsy and metabolically by CT-PET. A training set of 10 pts was evaluated by both BM biopsy and CT-PET to verify the diagnostic performance of CT-PET in identifying BM metastases (M+). We found a 100% concordance between BM biopsy and CT-PET and we therefore used CT-PET for further analyses. The CellSearch System (Veridex LLC, Raritan, NJ, USA) was used for the isolation and enumeration of CTCs in peripheral blood. The Student's t-test and the two-way ANOVA test were used to compare means of CTCs among patients with different metastatic patterns. Results: The CTCs mean and median scores of 129 MBC pts were analysed. Final analysis focused on 101 pts with bone M+. Thirty-three pts had bone M+ alone and 68 pts had bone and visceral M+ (including lymphnodes, brain, liver and lung/pleura). Number of metastatic sites was 1, 2, 3, 4, 5 in 30%, 37%, 25%, 6% and 2% of pts, respectively. BM involvement was documented in 27 (27%) of pts in the whole series and in 12 (33%) of pts with bone M+ alone. Mean CTCs score in the whole series was 392 (0-9993) and the median number of CTCs was 20. In the whole series, BM involvement was associated with higher mean CTCs scores (1350 vs 42, p .014). In pts with bone M+ alone, mean CTCs score was 696 (0-7000) and pts with BM involvement had higher mean CTCs scores (1846 vs 39, p 0.37). Among the different metastatic patterns, the association of bone with BM involvement and liver M+ was correlated with the highest CTCs numbers. We could not perform comparisons in the 68 pts with both bone and visceral localizations because of the variety of metastatic patterns. However, the two-way ANOVA showed a significant influence of BM involvement on mean CTCs scores in pts with different metastatic patterns (p >.001). Conclusions: This work confirms that pts with bone metastases have higher numbers of CTCs than pts with visceral metastases. Extensive bone disease with BM involvement is characterized by an increase in CTCs numbers compared to bone disease without BM involvement. Bone marrow metastases are metabolically more active by CT-PET and can be accurately detected by metabolic imaging without need of BM biopsy. Further studies are ongoing. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-19.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have